Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$5.49MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Evert Schimmelpennink
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 152
- Beta
- 1.63
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.54
Financials
Revenue
$5.49M+9.7%Net Income
$-31.92MEBITDA
$-31.80MFree Cash Flow
$-38.73MEPS (diluted)
$-1.02Shares Outstanding (diluted)
31.37M+278.1%Operating Expenses
$39.38MCash & Debt
$220.00MReturn of Capital
$0.00Revenue by Segment (annual)
$19.09MDividend per Share
$7.21Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.09M | $-82.13M | $-2.85 |
| 2024 | $0.00 | $-49.77M | $-2.34 |
| 2023 | $0.00 | $-69.97M | $-15.30 |
| 2022 | $15.00M | $-10.81M | $-12.89 |
| 2021 | $0.00 | $-70.76M | $-8.54 |
| 2020 | $0.00 | $-68.37M | $-8.24 |
| 2019 | $0.00 | $-109.0K | $-0.01 |
Valuation
LENZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57-65.31%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·31d ago·Neutral
LENZ Therapeutics: Still Speculative But Priced For Disasters LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Positive
LENZ Therapeutics Q2 Earnings Call Highlights LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.
View source ↗ - Newszacks.com·55d ago·Neutral
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-1.02 per share
Typical surprise +2.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-1.02 vs $-1.05beat
- Mon, May 11$-1.32 vs $-1.10miss
- Tue, Mar 24$-1.16 vs $-0.91miss
- Wed, Nov 5$-0.59 vs $-0.67beat
- Wed, Jul 30$-0.53 vs $-0.58beat
- Wed, May 7$-0.53 vs $-0.55beat
Estimates and results for LENZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LENZ officers and directors.
- Bought
- $16.2m
- Sold
- $66.9m
10 trades
36 trades
- George Jeffrey P.bought
- Schimmelpennink Evert B.bought
- Chevallard Daniel R.bought
- Olsson Shawnsold
- Olsson Shawnsold
- Mccollum James Wbought
- Chevallard Daniel R.bought
- Chevallard Daniel R.bought
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LENZ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.